Clinical Study "Common" Name (formal title)	Number of enrollees	Funding source (pharma/NIH)	Year complete	Primary publication	Full study treatment protocol
HARBOR	1097	Genentech	2012	Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046-1056. https://www.aaojournal.org/article/S0161-6420(12)00986-4/fulltext   Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121:2181-2192. https://www.aaojournal.org/article/S0161-6420(14)00429-1/fulltext